Search bioRxiv⌕ Search

Biology subjects

Girardi, J.

Publications and source records attributed to Girardi, J..

2 recordsLinked to original sources

Genetic diversity of Collaborative Cross mice enables the establishment of a novel Chlamydia muridarum female genital tract infection model

Chlamydial infection in women displays wide variation in bacterial burden, persistence, and risk of upper genital tract pathology, yet the host genetic factors underlying this heterogeneity remain poorly defined. We evaluated genital tract infection with Chlamydia muridarum across 20 Collaborative Cross (CC) strains, a recombinant inbred mouse panel that captures broad genetic diversity with high within-strain reproducibility. CC strains exhibited striking differences in early bacterial burden, time to clearance, and oviduct pathology, including prolonged low-inflammatory infections and burden-pathology discordance that mirror key features of human disease. Heritability analyses demonstrated that host genetics accounted for most of the variation observed in Day 7 bacterial burden and pathological outcomes. Genome-wide scans identified suggestive quantitative trait loci associated with both traits. Genes within the burden-associated locus converged on host pathways implicated in chlamydial intracellular growth, including membrane dynamics and lipid metabolism, ubiquitin signaling, host cell survival mechanisms, and immune regulatory signaling. In contrast, genes within the pathology-associated locus were enriched for pathways regulating inflammatory cell recruitment, inflammasome activation, and tissue remodeling, processes central to genital tract damage following infection. Cervical transcriptional profiling further revealed strain-dependent innate and adaptive immune programs associated with bacterial burden and disease phenotype. Together, these findings establish the CC as a powerful platform for dissecting the genetic architecture of chlamydial immunopathogenesis, and for improving preclinical evaluation of vaccines and therapeutics.

immunology↗

Intranasal immunization with CPAF combined with cyclic-di-AMP induces a memory CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum

Chlamydia trachomatis (Ct) is the most common bacterial sexually transmitted infection globally, and a vaccine is urgently needed to stop transmission and disease. Chlamydial Protease Activity Factor (CPAF) is an immunoprevalent and immunodominant antigen for CD4 T cells and B cells, which makes it a strong vaccine candidate. Due to the tolerogenic nature of the female genital tract (FGT) and its lack of secondary lymphoid tissue, effective induction of protective cell-mediated immunity will likely require potent and safe mucosal adjuvants. To address this need, we produced CPAF in a cell-free protein synthesis platform and adjuvanted it with the TLR9-agonist CpG1826, STING (stimulator of interferon genes) agonist cyclic-di-AMP (CDA), and/or the squalene oil-in-water nanoemulsion, AddaS03. We determined that intranasal immunization with CPAF plus CDA was well tolerated in female mice, induced CD4 T cells that produced IL-17A or IFN{gamma}, significantly reduced bacterial shedding, and shortened the duration of infection in mice intravaginally challenged with Chlamydia muridarum. These data demonstrate the potential for CDA as a mucosal adjuvant for vaccines against Chlamydia genital tract infection.

immunology↗